


IFW



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>Application Number</b>	10/531,495 ✓		
	<b>Filing Date</b>	April 15, 2005	
	<b>First Named Inventor</b>	Michael J. Breslin	
	<b>Art Unit</b>	To be determined	
	<b>Examiner Name</b>	To be determined	
<b>Total Number of Pages in This Submission</b>	-	<b>Attorney Docket Number</b>	21231YP

## ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<b>Remarks</b> - 19 References Attached - Explanation of Relevance of Non-English Documents Under 37 C.F.R. 1.98(a)(3)(i)		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

<b>Name</b>	David A. Muthard	<b>Registration No. (Attorney/Agent)</b>	35,297
<b>Signature</b>		<b>Date</b>	2/17/2006

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: 02/17/2006			
<b>Typed or printed name</b>	David A. Muthard		
<b>Signature</b>		<b>Date</b>	2/17/06



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. Breslin, et al.

Serial No. 10/531,495

Filed: April 15, 2005

For: MITOTIC KINESIN INHIBITORS

Art Unit: To be determinedExaminer: To be determined

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.


3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK &amp; CO., INC.

By  Date 2/17/06



## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: David A. Muthard

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 35,297

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3903

Date: February 17, 2006

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

### COMPLETE IF KNOWN

Application Number	10/531,495
Filing Date	April 15, 2005
First Named Inventor	Michael J. Breslin
Group Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	21231YP

Sheet

1

of

2

Use as many sheets as necessary)

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		6,057,342		Fevig, et al.	05/02/2000
		3,644,414		Helsey, et al.	02/22/1972
		6,440,686		Sakowicz	08/27/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 03/105855		Merck & Co., Inc.	12/24/2003
		PCT	WO 93/20099		Yamanouchi Pharm. Co., Ltd.	10/14/1993
		PCT	WO 2005/019206		Merck & Co., Inc.	03/03/2005
		PCT	WO 2005/019205		Merck & Co., Inc.	03/03/2005
		PCT	WO 03/106417		Merck & Co., Inc.	12/24/2003
		EPO	EP 418,845		Fujisawa Pharm. Co., Ltd.	06/30/2005

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/531,495	
			Filing Date	April 15, 2005	
			First Named Inventor	Michael J. Breslin	
			Group Art Unit	To be determined	
			Examiner Name	To be determined	
Sheet	2	of	2	Attorney Docket Number	21231YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		M. J. Breslin, et al., Database CALPUS on STN, DN:139:307756 (2003)
		M. Bujard, et al., Tetrahedron Letters (40), pgs. 8785 - 8788 (1999)
		M.J.S. Carpes, et al., Synlett., No. 7, pgs. 1037 - 1039 (2000)
		C. Sonesson, et al., J. Org. Chem. 1996, Vol. 61, pg. 4756-4763
		N. Iwasawa, et al., J. Org. Chem. 1998, Vol. 63, pg. 3164-3165
		N. Iwasawa, et al., J. Org. Chem. 1997, Vol. 62, pg. 1918-1919
		R. Mison, et al., J. Chem. Research(S), 1989, 126-127
		O. Yebdri, et al., Bulletin De La Societe Chimique de France, 1983, pg. 195-201
		A. Ranjon, Bulletin De La Societe Chimique de France, 1971, pg. 2068-2072
		A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621
		N. Moss, et al., J. Med. Chem., Vol 36 (20) pgs. 3005-3009 (1993)
		M. Fraley, et al., "Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters (2006)
		R. Garbaccio, et al., "Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorganic & Medicinal Chemistry Letters (2006)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005